Evidence map›Paper›PMID 35467307›Full record

ReviewEJNMMI radiopharmacy and chemistry2022

Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.

Martha Sahylí Ortega Pijeira, Herlys Viltres, Jan Kozempel, Michal Sakmár, Martin Vlk, Derya İlem-Özdemir, Meliha Ekinci, Seshasai Srinivasan, Amin Reza Rajabzadeh, Eduardo Ricci-Junior and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Martha Sahylí Ortega PijeiraLaboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rua Helio de Almeida, 75, Ilha Do Fundão, Rio de Janeiro, RJ, 21941906, Brazil.
Herlys ViltresSchool of Engineering Practice and Technology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
Jan KozempelDepartment of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519, Prague 1, Czech Republic.
Michal SakmárDepartment of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519, Prague 1, Czech Republic.
Martin VlkDepartment of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519, Prague 1, Czech Republic.
Derya İlem-ÖzdemirDepartment of Radiopharmacy, Faculty of Pharmacy, Ege University, 35040, Bornova, Izmir, Turkey.
Meliha EkinciDepartment of Radiopharmacy, Faculty of Pharmacy, Ege University, 35040, Bornova, Izmir, Turkey.
Seshasai SrinivasanSchool of Engineering Practice and Technology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
Amin Reza RajabzadehSchool of Engineering Practice and Technology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
Eduardo Ricci-JuniorSchool of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, 21940000, Brazil.
Luciana Magalhães Rebelo AlencarLaboratory of Biophysics and Nanosystems, Department of Physics, Federal University of Maranhão, Campus Bacanga, São Luís, Maranhão, 65080-805, Brazil.
Mohammed Al QahtaniCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital & Research Centre, Riyadh, 11211, Saudi Arabia.
Ralph Santos-OliveiraLaboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rua Helio de Almeida, 75, Ilha Do Fundão, Rio de Janeiro, RJ, 21941906, Brazil. roliveira@ien.gov.br.ORCID http://orcid.org/0000-0002-7221-6404

Funding

cnpq Bolsa Produtividade 1B
6 · The paper itself

Abstract

backgroundRecent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health fields, uses nanoparticles for several applications such as imaging, diagnostic, targeted cancer therapy, drug and gene delivery, tissue engineering, and theranostics.

resultsHere, we overview the current state-of-the-art of radiolabeled nanoparticles for molecular imaging and radionuclide therapy. Nanostructured radiopharmaceuticals of technetium-99m, copper-64, lutetium-177, and radium-223 are discussed within the scope of this review article.

conclusionNanoradiopharmaceuticals may lead to better development of theranostics inspired by ingenious delivery and imaging systems. Cancer nano-theranostics have the potential to lead the way to more specific and individualized cancer treatment.

Indexed as

Copper-64Lutetium-177Molecular imagingRadiolabeled nanoparticlesRadionuclide therapyRadiopharmacyRadium-223Technetium-99mTheranosticsToxicity

Identifiers

PMID35467307
PMCPMC9038981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.